GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study
Status:
Completed
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Pioglitazone is an approved anti-hyperglycemic medication and is thought to have
anti-inflammatory properties. This study seeks to gather safety and tolerability data related
to pioglitazone when given to patients who require hospital admission for confirmed positive
COVID-19 infections with elevated blood sugar levels as compared to patients who did not
receive pioglitazone during their hospitalization for COVID-19.